Funding for this research was provided by:
National Research Foundation of Korea (NRF-2021R1I1A1A0104944111)
Yongin Severance Hospital (Z-2023-0008)
Korea Health Industry Development Institute (RS-2023-00262087)
Article History
Received: 29 November 2023
Accepted: 5 February 2024
First Online: 23 February 2024
Declarations
:
: JY reports research grants from Chong Kun Dang pharmaceutical. MB reports research grants from Dae Woong pharmaceutical. JK reports research grants from Chong Kun Dang pharmaceutical and Myung In pharmaceutical. JJ reports no conflict of interest.
: This study was approved by the Institutional Review Board of Yongin Severance Hospital (9-2022-0169), and the requirement for informed consent was waived because of the retrospective nature of the study and the use of fully anonymized data from NHIS-HEALS.
: Not applicable.